Evidence map›Paper›PMID 28722603›Full record

ArticleThe American journal of tropical medicine and hygiene2017

Molecular Characterization of

Barbara Molina-Moya, Michel Kiréopori Gomgnimbou, Carmen Lafoz, Alicia Lacoma, Cristina Prat, Guislaine Refrégier, Sofia Samper, Jose Dominguez, Christophe Sola

Abstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Genetic characterization ofInfection and drug resistance · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Barbara Molina-MoyaCIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Michel Kiréopori GomgnimbouCentre Muraz, Bobo-Dioulasso, Burkina Faso.
Carmen LafozInstituto Aragonés de Ciencias de la Salud, Fundación Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Alicia LacomaCIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Cristina PratCIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Guislaine RefrégierInstitut de Biologie Intégrative de la Cellule (I2BC), CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette, France.
Sofia SamperInstituto Aragonés de Ciencias de la Salud, Fundación Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Jose DominguezCIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Christophe SolaInstitut de Biologie Intégrative de la Cellule (I2BC), CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated Tuberculosis-Spoligo-Rifampicin-Isoniazid Typing (TB-SPRINT), a microbead-based method for spoligotyping and detection of rifampicin and isoniazid resistance in

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialGenotypeIsoniazidMicrobial Sensitivity TestsMolecular TypingMycobacterium tuberculosisRifampinSensitivity and SpecificityAntitubercular AgentsIsoniazidRifampin

Identifiers

PMID28722603
PMCPMC5590574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.